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Abstract
Background: China will experience an overall growth and aging of its adult population in coming decades. We used a
computer model to forecast the future impact of these demographic changes on coronary heart disease (CHD) in China.
Methods: The CHD Policy Model is a validated state-transition, computer simulation of CHD on a national scale. China-
specific CHD risk factor, incidence, case-fatality, and prevalence data were incorporated, and a CHD prediction model
was generated from a Chinese cohort study and calibrated to age-specific Chinese mortality rates. Disability-adjusted life
years (DALYs) due to CHD were calculated using standard methods. The projected population of China aged 35–84
years was entered, and CHD events, deaths, and DALYs were simulated over 2000–2029. CHD risk factors other than
age and case-fatality were held at year 2000 levels. Sensitivity analyses tested uncertainty regarding CHD mortality
coding, the proportion of total deaths attributable to CHD, and case-fatality.
Results: We predicted 7.8 million excess CHD events (a 69% increase) and 3.4 million excess CHD deaths (a 64%
increase) in the decade 2020–2029 compared with 2000–2009. For 2030, we predicted 71% of almost one million annual
CHD deaths will occur in persons 65 years old, while 67% of the growing annual burden of CHD death and disability
will weigh on adults <65 years old. Substituting alternate CHD mortality assumptions led to 17–20% more predicted
CHD deaths over 2000–2029, though the pattern of increases in CHD events and deaths over time remained.
Conclusion: We forecast that absolute numbers of CHD events and deaths will increase dramatically in China over
2010–2029, due to a growing and aging population alone. Recent data suggest CHD risk factor levels are increasing, so
our projections may underestimate the extent of the potential CHD epidemic in China.
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Background
China, the most populous of nations, will have a growing
and aging population in coming decades. China's popula-
tion was 1.27 billion in 2000, with seven percent of the
population  65 years old; by 2030 the population is pre-
dicted to be 1.46 billion, and 16% percent of Chinese cit-
izens will be  65 (Figure 1).[1,2] The aging of the
population is due both to a boom in births in China dur-
ing the 1950's to early 1970's and to an increased life
expectancy for many Chinese.[3] The latter phenomenon
has been attributed to the "epidemiologic transition" – a
shift away from illnesses that cause mortality in the young
(e.g., infectious and maternal/fetal diseases) toward
chronic diseases that affect the old. [4-8]
Cardiovascular disease is already the leading cause of
mortality in China, and coronary heart disease (CHD) is
the 4th leading cause. [8-10] Past analyses have estimated
the future societal consequences of cardiovascular disease
in China,[9] and analyzed the increasing CHD mortality
trend in Beijing.[11] We sought to quantify the extent to
which population growth and aging alone would impact
the epidemic of CHD in China in coming decades in
greater detail and on a national scale. We built upon the
CHD Policy Model, a computer predictive model that was
initially developed for the United States,[12] adapted the
model for use in China, and forecasted CHD events and
disability-adjusted life years (DALYs) in Chinese adults
from 2000–2029. In this baseline analysis, levels of CHD
risk factors other than age [i.e., blood pressure (BP), cho-
lesterol, body mass index (BMI), diabetes, and smoking]
were held constant over time. We also conducted sensitiv-
ity analyses in order to examine the impact of future
demographic changes on CHD in China under variable
cause-specific mortality and CHD case-fatality assump-
tions.
Methods
The Coronary Heart Disease Policy Model
The CHD Policy Model is a computer-simulation, state-
transition (Markov cohort) model that has been used for
20 years to predict CHD incidence, prevalence, mortality,
and costs in U.S. adults aged 35–84. [12-22] The CHD
Policy Model-China is comprised of three submodels: the
demographic-epidemiologic submodel, the bridge sub-
model, and the disease history submodel. The demo-
graphic-epidemiologic submodel predicts CHD incidence
and non-CHD mortality among the population without
CHD, stratified by age, sex, and up to six additional cate-
gorized risk factors: systolic blood pressure (BP, <120,
120–139, 140 mmHg), smoking status (active smoker,
non-smoker with exposure to environmental tobacco
smoke, non-smoker without environmental exposure),
high density lipoprotein (HDL) cholesterol [<0.9, 0.9–
1.3, or >1.3 mmol/L (<35, 35–49, >49 mg/dL)], low-den-
sity lipoprotein (LDL) cholesterol [<2.6, 2.6–3.4, or >3.4
mmol/L (<100, 100–130, >130 mg/dL)], BMI (<25, 25–
29, >29 kg/m2), and diabetes mellitus (yes or no). After
CHD develops, the bridge submodel characterizes the ini-
tial CHD event and its sequelae for 30 days. Then, the dis-
ease history submodel predicts subsequent CHD events,
revascularization procedures, CHD mortality, and non-
CHD mortality among patients with CHD. All population
distributions, risk factor levels, coefficients, event rates,
and case fatality rates can be modified for forecasting sim-
ulations. Additional methods for the Policy Model-China
are provided in Additional file 1. A general description of
the United States version of the CHD Policy Model soft-
ware is available elsewhere.[23]
Overview of China-specific model inputs
The current analysis introduces the CHD Policy Model-
China, a model modified and calibrated to predict CHD
in the Chinese population. We employed China-specific
data inputs from population-based studies wherever pos-
sible, including age- and sex-specific estimates of the Chi-
nese population distribution during 2000–2029, as well
as CHD incidence, prevalence, case-fatality, and mortal-
ity, non-CHD mortality, and rates of coronary revascular-
ization (Table 1).
Sino-MONICA, conducted from 1985–1993 in 17 moni-
toring units in 16 provinces of China, was a surveillance
sample of roughly 5,000,000 people, and Sino-MONICA
surveillance has continued from 1994 to the present in a
sub-population of approximately 170,000 people in Bei-
jing. [24-26] All acute coronary heart disease and stroke
events in persons 25–74 years old were registered using
the World Health Organization (WHO) Monitoring
Trends and Determinants in Cardiovascular Disease
(MONICA) project methodology and criteria.[24] The
Chinese Multi-provincial Cohort Study (CMCS).
Age distribution of the Chinese population in 2000 and 2030 Figure 1
Age distribution of the Chinese population in 2000 
and 2030. Distributions are based on U.S. Census Bureau 
International Database projections.
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[27] recruited 27,003 participants from 11 provinces of
China in 1992–1993. An additional 3,118 participants
were added in 1996 and 1999. Prevalent cases of CHD
were excluded at baseline, and baseline variables meas-
ured. The cohort was followed for 10 years for CHD and
non-CHD events and deaths, using MONICA case finding
methods and criteria.[24]
The International Collaborative Study of Cardiovascular Dis-
ease in Asia Study (InterASIA).[28] enrolled a nationally-
representative multistage cluster sample of 15,838 Chi-
nese adults, aged 35–74 years in 2000–2001. Fasting glu-
cose, BP, BMI, and LDL and HDL cholesterol were
measured. Demographic, medical history, and tobacco
exposure information was collected in interviews. The
China National Hypertension Survey Epidemiology Follow-up
Study (CHEFS) [8] used a multi-stage, random clustering
design to identify a nationally-representative sample of
83,533 men and 86,338 women older than age 40 who
were eligible for follow-up beginning in 1991. Follow-up
mortality data were gathered from 158,666 participants or
proxies by interview in 1999 (93.4% follow-up rate).
The Bridging the Gap in CHD secondary prevention (BRIG)
Study  is an ongoing longitudinal survey of Chinese
patients diagnosed with CHD and aims to measure adher-
ence to evidence-based inpatient and outpatient CHD
management practices representative of all of China.
BRIG sampled 64 hospitals (32 tertiary and 32 secondary-
level hospitals) located in 22 provinces, five autonomous
regions, and four municipalities located in urban and
rural areas throughout China (Personal communication,
Jun Cheng, MD, September, 2008). At the time of this
analysis, the BRIG study had recruited 3,174 participants
hospitalized for an acute CHD event (48.7% acute myo-
cardial infarction, 45.6% unstable angina, 5.4% ill-
defined CHD). Information was collected regarding
patients' demographic characteristics, medical history,
presenting symptoms, electrocardiographic findings, bio-
chemical examinations, cardiac biomarker assays, clinical
characteristics, use of cardiac medications, and revascular-
ization procedures, including percutaneous coronary
intervention (PCI), coronary artery bypass graft surgery
(CABG), and thrombolysis. Overall rates of revasculariza-
tion for acute myocardial infarction in the BRIG study
were 31% in men and 17% in women. All costs and hos-
pital-associated and outpatient outcomes were recorded,
including outcomes of interventional procedures.
For most population-based studies in China, data were
available only for Chinese adults aged 35–74 years. We
therefore applied age-related trends in CHD incidence
from the Framingham Heart Study[29] and Olmsted
County, Minnesota, U.S.A.[30] and age-related trends in
case-fatality rates from the MONICA Study[31] and U.S.
National Hospital Discharge Survey and California Office
of Statewide Health Planning and Development hospital-
ization records[23] to estimate these parameters for the
75–84 year old category. Annual transition rates in risk
factor levels were calculated to preserve age-related risk
factor trends observed in the InterASIA survey in 2000–
2001 using methods developed for the United States CHD
Policy Model.[23]
Table 1: Primary model inputs and references for the coronary heart disease (CHD) Policy Model-China
Variable Source
Population of China 2000–2029* United States Census Bureau International Database,[1]
Chinese National Bureau of Statistics[2]
Incidence of CHD China Multi-provincial Cohort Study (CMCS),[27] 1992–2002
Sino-MONICA,[24] Beijing, 1993–2004
Prevalence of CHD in 2000 International Collaborative Study of Cardiovascular Disease in Asia 
Study (InterASIA),[28] 2000–2001
China National Hypertension Survey Epidemiology Follow-up Study 
(CHEFS),[8] 1991–2000
Total and Cause-Specific Mortality
Total For total mortality: Global Burden of Disease Study, 2002 [36]
CHD For cause-specific mortality:
Non-CHD CHEFS[8], Global Burden of Disease Study, 2002 [36]
CHD risk factor means and joint distributions, 2000 InterASIA [28,52-55,59]
Risk factor hazards for CHD CMCS [27]
One-day and 28-day CHD case-fatality Sino-MONICA, Beijing 1993–2004 [24]
Revascularization rates Bridging the Gap in Coronary Heart Disease Secondary Prevention 
(BRIG) Study 2006-present (unpublished data, provided by personal 
communication, Dong Zhao, M.D., Ph.D., March, 2007)
Disability Adjusted Life Years (DALY) disability weights and assumptions Global Burden of Disease Study, 2001[35]BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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Population Assumptions
The estimated population of China aged 35–84 years in
thee year 2000, by age and sex, was entered from the
United States Census Bureau International Database,
because that database provided both the Chinese popula-
tion in 2000 and projections of the population between
the years 2001–2029.[1] Year 2000 estimates from this
database were compared with estimates from the National
Bureau of Statistics, China, and found to be similar for
this age range.[32] Numbers of 35 year old adults entering
the model from the year 2001 to the year 2030 were also
entered from U.S. Census Bureau International Database
projections.
Mortality Assumptions
The CHD Policy Model-China defined CHD as myocar-
dial infarction (ICD-9 410, 412 or ICD-10 I21, I22),
angina and other CHD (ICD-9 411, 413 and 414, or IC-
10 I20, I23–I25), and a fixed proportion of "ill-defined"
cardiovascular disease coded events and deaths (ICD-9
codes 427.1, 427.4, 427.5, 428, 429.0, 429.1, 429.2,
429.9, 440.9 or ICD-10 I47.2, I49.0, I46, I50, I51.4, I51.5,
I51.9, and I70.9).[33] Misclassification of CHD deaths
into ill-defined cardiovascular disease codes occurs in
many nations, resulting in gross underestimation of CHD
mortality. Lozano et al. developed regression equations
using standard CHD death rates and the relative risk of
CHD attributable to national smoking prevalence to
develop correction factors for the ill-defined cardiovascu-
lar code use in high- and low-miscoding nations.[33]
Because the CHEFS codes less than 1% of all deaths into
these ill-defined codes (well below the international
median of 5%),[34] in our base model we employed a
highly specific approach and attributed the small age- and
sex- specific proportions of deaths categorized with ill-
defined codes recommended by the World Health Organ-
ization for "low ill-defined cardiovascular disease coding"
countries.[33,35] In a sensitivity analysis, we repeated our
model simulation after calibrating the model to match the
higher number of CHD deaths resulting when a larger
proportion of ill-defined coded deaths are classified as
CHD deaths (using correction factors advised for "high ill-
defined cardiovascular disease coding" countries, Table 2)
[33,35]
We assumed the same number of total deaths in China for
the year 2002 reported by the Global Burden of Disease
Study, [36] an estimate that adjusted for underreporting
of deaths in the 2000 Chinese Census.[35,37] In our main
simulation, we assumed age- and sex-specific proportions
of total deaths attributable to CHD estimated by the
nationally-representative CHEFS. Deaths identified in
CHEFS survey households were verified using hospital
records (when available) and death certificates. Cause of
death was assessed and at times revised after review by an
assessment committee in each province, and a study-wide
end-point committee at the Chinese Academy of Medical
Sciences in Beijing conducted an additional independent
review before determining the cause of each death.[8]
Global Burden of Disease Study cause-specific mortality
data for China in 2002 were estimated from two distinct
Chinese government sources: the Ministry of Health-Vital
Registration System, and the Disease Surveillance Points
system.[35] In order to demonstrate the impact of uncer-
Table 2: Variability in the estimated proportions of deaths due to coronary heart disease in China.
Age and sex category CHEFS* with conservative ICD 
definition of CHD (main 
assumption)†
CHEFS with liberal ICD 
definition of CHD‡
Global Burden of Disease 
estimates, 2002[36]
Men
35–44 years 0.04 0.04 0.03
45–54 0.04 0.05 0.06
55–64 0.08 0.10 0.07
65–74 0.08 0.09 0.09
75–84 0.06 0.08 0.06
Women
35–44 years 0.03 0.03 0.03
45–54 0.06 0.05 0.06
55–64 0.07 0.09 0.08
65–74 0.08 0.09 0.10
75–84 0.05 0.06 0.11
* China National Hypertension Survey Epidemiology Follow-up Study
†CHD defined as myocardial infarction (ICD-9 410, 412 or ICD-10 I21, I22), angina and other CHD (ICD-9 411, 413 and 414, or IC-10 I20, I23–
I25), and a fixed proportion of "ill-defined" cardiovascular disease coded events and deaths.[33] (ICD-9 codes 427.1, 427.4, 427.5, 428, 429.0, 429.1, 
429.2, 429.9, 440.9 or ICD-10 I47.2, I49.0, I46, I50, I51.4, I51.5, I51.9, and I70.9). The conservative definition of CHD assumed that very few CHD 
deaths were misclassified into ill-defined cardiovascular codes, so few of those deaths were counted as CHD deaths.
‡The more liberal coding method used the same ICD codes described above, but assumed that a higher proportion of CHD deaths were mis-
coded into the "ill-defined" cardiovascular codes, so more deaths assigned these ill-defined codes are counted as CHD deaths.[33]BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
Page 5 of 14
(page number not for citation purposes)
tainty regarding mortality assumptions and ensure com-
parability with the Global Burden Study and other
studies,[38] we conducted a sensitivity analysis assuming
the age-specific CHD mortality rates employed by the
Global Burden of Disease Study for 2002. (Data from per-
sonal communication, Colin D. Mathers, Ph.D., April,
2008) The proportion of total deaths assigned to CHD
assumed by the Global Burden Study was markedly higher
in women of all ages compared with CHEFS estimates
(Table 2).
CHD Incidence, Prevalence, and Case-fatality
Age- and sex- specific incidence of CHD in the population
with no prior CHD was based on the incidence observed
in the CMCS cohort study. Rates of repeat CHD events in
the population diagnosed with CHD was estimated from
data from Canada and the U.S. [39-42] Initially, preva-
lence of CHD in the model's base year was estimated from
the prevalence of a self-reported history of myocardial inf-
arction (answered yes to "has your doctor told you that
you had a heart attack?") or definite or possible angina
recorded using the Rose questionnaire[43] in the InterA-
SIA Study.[28] Because self-reported angina prevalence in
the base year of 2000 was thought to be the most unrelia-
ble epidemiologic parameter (due possibility to a high
number of false-positive angina diagnoses made with the
Rose questionnaire [34,44]) the prevalences of self-
reported angina and total CHD were adjusted to fit with
angina (cases presenting for medical attention and coded
ICD-9 413) and overall CHD incidence observed in the
CMCS. Case-fatality rates increased by 1% annually in the
MONICA Beijing population during 1984–1993,[45] but
have been declining since (personal communication,
Dong Zhao, M.D., Ph.D., April, 2008). In light of these
dynamic changes, we took a conservative approach and
assumed no case-fatality trend, but did model the conse-
quences of assuming higher and lower case-fatality rates
in sensitivity analyses. Incidence and fatality data over the
years 1993–2004 were estimated from pooled Beijing
Sino-MONICA Study data, and the main age-specific
CHD case-fatality rate assumptions were estimated from
the overall rates. Twenty-eight day case-fatality rates for
ages 25–74 years in the Beijing Sino-MONICA population
were 53% for Chinese men and 66% for Chinese women.
These rates were lower than rates assumed for China in
2000 by the Global Burden of Disease Study – 62% for
men and 72% for women.[34] In that analysis Global
Burden investigators began with Sino-MONICA (Beijing)
data from 1984–1993 and extrapolated these rates to the
year 1996. We performed two sensitivity analysis: one that
used the higher case-fatality rates assumed for China in
the Global Burden study for 2000, and another using the
lower case-fatalities observed in the Beijing Sino-MON-
ICA population since 1999 [average over 1999–2004 for
25–74 year old men (40%) and women (49%)].
CHD prediction and model calibration
The CHD Policy Model-China risk equation uses means
and  coefficients for age, sex, systolic BP, smoking status,
LDL, HDL, diabetes, and BMI. A separate non-CHD death
equation includes age, sex, systolic BP, diabetes, and
smoking status. Multivariate hazard ratios were estimated
for CHD risk factors with age- and sex-specific Cox pro-
portional hazards models using data from the CMCS, cen-
tered on age 50 years, with CHD or non-CHD death as the
outcome.[27] (Tables 3 and 4) Measurement of CHD risk
factors and formulation of Cox proportional hazards
models in the CMCS is described in detail elsewhere.[27]
In the Cox models, systolic BP, LDL cholesterol, HDL cho-
lesterol, and BMI were treated as continuous variables.
Statistically significant interactions of age with systolic BP
and of age with smoking were incorporated into the final
prediction model. The estimated risk for CHD from active
smoking in Chinese women in the CMCS is thought to be
unreliable (perhaps due the small number of female
smokers in the cohort),[27] so the estimate for CHD risk
from smoking in Chinese women participating in the
PRC-USA cohort study[46] was substituted into the CHD
risk equation, after adjusting the estimate to reflect risk for
total CHD (myocardial infarction, angina, or arrest)
rather than hard CHD (myocardial infarction or arrest
only).
Table 3: Multivariate Cox proportional hazard model hazard ratios for CHD risk in Chinese adults aged 35–74, the CMCS
Males Females
Variable Hazard Ratio 95%CI Hazard Ratio 95%CI
Age (10 years) 1.93 (1.57, 2.39) 1.99 (1.42, 2.79)
HDL (10 mg/dl or 0.26 mmol/l) 0.98 (0.88, 1.09) 0.78 (0.64, 0.93)
LDL (20 mg/dL or 0.51 mmol/l) 1.17 (1.10, 1.27) 1.11 (0.98, 1.24)
Systolic BP (20 mm Hg) 1.35 (1.17, 1.52) 1.27 (1.04, 1.55)
Diabetes (yes = 1, no = 0) 1.35 (0.82, 2.21) 2.43 (0.89, 3.47)
Active smoking (yes = 1, no = 0) 2.00 (1.45, 2.75) 2.51* Not available†
Excepting smoking in women, estimates are from a multivariate model containing all variables shown in the table.
*Hazard ratio for active smoking in women from the PRC-USA cohort (Wu et al.)[46] after adjusting the estimate to reflect total CHD (angina, 
myocardial infarction, and arrest) in place of hard CHD (myocardial infarction and arrest only). See text for explanation.
† 95% confidence interval for the original estimate was not published.BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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The model's incidence was calibrated to reproduce the
total number of deaths reported by the Global Burden of
Disease Study for the year 2002 [36] under fixed case-
fatality assumptions. Beginning with rates of CHD and
non-CHD deaths reported from the CHEFS[8], we
inflated CHD and non-CHD death rates proportionally
(by 30%) in the model's simulation of the year 2002 to
approximate the Global Burden of Disease estimate for
that year. We then ensured that the Model's age-specific
CHD and non-CHD death rates were constant over the
30-year simulation.
Disability-adjusted life years (DALYs) lost due to CHD
DALYs were used to estimate the future burden of fatal
and nonfatal CHD in China. The DALY measure com-
bines Years of Life Lost (YLL) to premature death and the
number of Years of life Lost due to Disability (YLD) using
a set of disease-specific weights that value the level of dis-
ability. DALY disability weights range from zero (no disa-
bility) to one (death or extreme disability). In the absence
of China-specific disability weights, the DALY weights
established by the Global Burden of Disease study have
the advantage of being generated in a standardized
method and have been shown to be valid across cul-
tures.[47]
YLL due to premature CHD death were calculated using a
Global Burden of Disease calculator,[48] with age-specific
life expectancies based on internationally standard life
tables (West Model Levels 25 and 26 for men and women,
respectively).[35] YLD were calculated by entering annual
predictions of non-fatal acute myocardial infarctions,
incident angina, and estimated incident heart failure.
Non-fatal acute myocardial infarctions were defined as
28-day survivors of MI, a condition assumed to be disa-
bling for a mean of 0.58 years with a DALY weight of
0.44.[34] Age- and sex-specific disability weights and dis-
ease durations were those assumed for China in 2004 for
the Global Burden of Disease Study (personal communi-
cation, Colin Mathers, Ph.D., August, 2008). [34] Angina
pectoris was assumed to persist for an average of 8.3 years
in men (aged 35–84 years) and 9.4 years in women (aged
35–84) with a DALY weight of 0.16.[34,49] It was
assumed that 20% of incident non-fatal myocardial inf-
arctions led to congestive heart failure,[34,50] which then
lasts for an average of 2.6 years in men (aged 35–84 years)
and 3.3 years in women (aged 35–84 years) with a DALY
weight of 0.25.[34,49] It was assumed that there was no
remission from either angina or heart failure.
Total annual DALYs and DALYs stratified by age < 65 or
65 years are reported. The Global Burden Study time-dis-
counted YLL and YLD at 3% annually after the year of
interest in primary analyses and used age weights, which
give less weight to younger and older ages in calculating
DALYs.[49] We decided a priori not to use discounting or
age weights in our primary estimates, but we do report dis-
counted (3%) and age-weighted DALY estimates from
sensitivity analyses.
Predicting the impact of population growth and aging on 
CHD in China from 2000–2029
We used the CHD Policy Model-China to predict the effect
of an aging and growing population on the epidemic of
CHD in China over 2000–2029. We entered the popula-
tion of China aged 35–84 in 2000 and the number of Chi-
nese becoming 35 years old annually from 2001–2029.[1]
Risk factors other than age were held constant at levels
measured in 2000–2001.[28,51-55] Case-fatality rates
were also held constant over future years. Annual absolute
numbers and rates of CHD events, CHD deaths, and non-
CHD deaths were tabulated over the 30 years of the simu-
lation. CHD predictions for individual years were used to
calculate YLL, YLD, and DALYs attributable to CHD for
the years 2000, 2010, 2020, and 2030. We subsequently
analyzed the independent effect of an aging population
on future CHD by stratifying annual predictions of deaths
and DALY by age 35–64 and age  65 years.
Results
CHD events and deaths in China, 2000–2029
For 2002, the 7,126,000 total deaths estimated from the
CHD Policy Model-China for Chinese adults aged 35–84
matched the 7,126,000 deaths reported by the Global
Burden of Disease Study for that year.[36] The Model esti-
mated there were 1,084,000 CHD events, 457,000 CHD
Table 4: Multivariate Cox proportional hazard model hazard ratios for non-CHD mortality, Chinese men aged 35–74, the CMCS, 
1992–2002.
Males Females
Variable Hazard Ratio 95%CI Hazard Ratio 95%CI
Age (10 years) 2.03 (1.78, 2.35) 1.72 (1.43, 2.06)
Systolic BP (20 mm Hg) 1.25 (1.15, 1.37) 1.32 (1.17, 1.46)
Diabetes (yes = 1, no = 0) 1.25 (0.90, 1.73) 1.22 (0.77, 1.93)
Active smoking (yes = 1, no = 0) 1.37 (1.12, 1.67) 2.02 (1.26, 3.26)
Estimates are from a multivariate model containing all variables shown in the table.BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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deaths, 472,000 non-fatal myocardial infarctions, and
227,000 new cases of angina pectoris in the model's base
year of 2000.
With BP, cholesterol, BMI, diabetes, and smoking held at
their 2000 levels, and case-fatality rates likewise held con-
stant, we predicted an estimated 3.4 million CHD events
and 1.4 million CHD deaths will occur over 2010–2020
in excess of the absolute numbers for 2000–2009 (Table
5), and 7.8 million excess CHD events and 3.4 million
CHD deaths over 2020–2029 compared with the absolute
numbers predicted for 2000–2009. There will be an esti-
mated 64% increase in the number of CHD events in Chi-
nese adults 35–84 years old in the third decade 2020–
2029 compared with 2000–2009 (61% increase in men;
69% increase in women). With CHD risk factors other
than age held constant, the number of non-CHD deaths
in Chinese adults (including stroke deaths) was predicted
to increase by 59% in 2020–2029 compared with 2000–
2009 (Table 5).
The aging of the Chinese population was reflected in the
predicted rise in the overall rates of CHD events and
deaths, which were most pronounced in the third decade
2020–2029 (Figures 2a, b). Due to the aging of the Chi-
nese population, CHD deaths in the simulation increased
68% in persons 65–84 years old in 2020–2029 compared
with 2000–2009, whereas the increase in CHD deaths was
only 57% in adults 35–64 years old. In 2000, 2010, 2020,
and 2030, two-thirds or more of the growing number of
annual CHD deaths occurred in persons  65 years old
(Figure 3).
Future burden of CHD death and disability in China
Predicted annual DALYs attributable to CHD were largely
driven by years of life lost due to CHD mortality, and
annual DALYs increased with each successive decade in
China (Table 6). When DALYs were stratified by age <65
or  65 years old, a greater number of DALYs and more
than two-thirds of the burden of CHD was persistently
concentrated in the population <65 years old, despite the
higher proportions of CHD deaths in the population  65
(Figure 4).
Sensitivity Analyses
When we assumed that a higher proportion of deaths
assigned to ill-defined cardiovascular ICD codes were in
fact due to CHD, we estimated 215,000 more CHD events
and 76,000 more CHD deaths in the year 2000 than we
did with our base model. Assuming the higher propor-
tions of total deaths attributable to CHD reported by the
Global Burden of Disease Study resulted in an additional
233,000 predicted CHD events and 96,000 predicted
CHD deaths for 2000. Most of the excess was in women,
in whom almost 50% more CHD deaths were predicted
under this assumption compared with the main simula-
tion. The pattern of additional CHD events and deaths
under the more liberal ICD coding or the Global Burden
Study's higher proportion of CHD deaths continued
through the 30-year simulation, leading to a substantial
cumulative number of incremental CHD events and
deaths compared with the main simulation (Table 7). In
the sensitivity analysis assuming higher CHD case-fatality
rates, estimates of CHD events were identical to the base
model in 2000, but there were 143,000 additional CHD
deaths. Over a 30-year simulation, assuming higher case-
fatality rates resulted in >20% higher cumulative mortal-
ity estimates (Table 7). Compared with the base model,
Table 5: Main simulation: predicted coronary heart disease (CHD) events and deaths and non-coronary deaths in Chinese adults 35–84 
years old within three successive decades, 2000–2029, the CHD Policy Model-China.
Decade Person-Years, China Coronary Heart
Disease Events
Coronary Heart
Disease Deaths
Non-CHD Deaths
2000–2009 Total 5,728,376,000 12,259,000 5,228,000 71,000,000
Men 2,911,466,000 7,758,000 3,156,000 41,675,000
Women 2,816,911,000 4,502,000 2,073,000 29,324,000
2010–2019 Total 6,867,272,000 15,650,000 6,670,000 89,936,000
Men 3,445,402,000 9,843,000 4,020,000 52,707,000
Women 3,421,870,000 5,806,000 2,650,000 37,229,000
2020–2029 Total 7,692,894,000 20,098,000 8,580,000 114,718,000
Men 3,817,832,000 12,467,000 5,094,000 66,301,000
Women 3,875,062,000 7,631,000 3,486,000 48,416,000
2000–2029 Total 20,288,542,000 48,007,000 20,478,000 275,654,000
Men 10,174,670,000 30,068,000 12,269,000 160,684,000
Women 10,113,843,000 17,939,000 8,209,000 114,970,000BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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overall CHD event rates diminished over time under a
higher CHD case-fatality assumption, because while rates
of new CHD events were unchanged, fewer chronic CHD
patients in the Disease History portion of the model led to
fewer repeat CHD events. Assuming the lower case-fatality
rates observed recently in the Beijing Sino-MONICA pop-
ulation led to a similar estimated incidence but 20% fewer
estimated CHD deaths. Assuming a lower case-fatality rate
also led to a 12% higher predicted prevalence of CHD
over the entire simulation (11% higher in men; 13%
higher in women).
Adding Global Burden of Disease age weights (but no dis-
counting) led to lower estimates of 5.4, 7.2, 8.8, and 10.6
million CHD-related DALYs for the years 2000, 2010,
2020, and 2030, respectively. With age weights added, the
projected proportions of total CHD DALYs attributable to
the adult population <65 years old were 77% for 2000,
78% for 2010, 76% for 2020, and 73% for 2030. Dis-
counting future DALYs at 3%, but using no age weights
resulted in estimates of 6.1, 8.1, 10.1, and 12.6 million
CHD DALYs for 2000, 2010, 2020, and 2030, respec-
tively, and lower percentages of total CHD DALYs for the
adult population <65 years old (67%, 68%, 67%, and
63%). Applying both a 3% discount to DALYs for future
years and age weights led to the lowest CHD DALY esti-
mates: 4.1, 5.5, 6.7, and 8.2 million for 2000, 2010, 2020,
and 2030, respectively, and 74%, 75%, 73%, and 71% of
total CHD DALYs attributed to the adult population <65
years old.
Discussion
It is well known that the population of China is growing
and aging. Using the CHD Policy Model-China, which
incorporated China-specific data, we projected an excess
of at least 7.8 million CHD events and 3.4 million CHD
deaths over 2020–2029 compared with 2000–2009, even
when holding levels of CHD risk factors constant, based
on forecasted population growth and aging of the Chinese
population.
The independent effect of aging on increasing CHD
deaths will be greatest after 2020. Despite the more pro-
nounced increase in CHD deaths in the population  65
years old, our DALY estimates indicated that the greatest
direct disease burden of CHD will remain in the popula-
tion <65. The impact of non-fatal CHD in older Chinese
people will have a particularly profound indirect effect on
their working-age children: the population of China is
a. Predicted ten year rates of coronary heart disease (CHD)  events in Chinese men and women aged 35–84, 2000–2029  from the CHD Policy Model-China Figure 2
a. Predicted ten year rates of coronary heart disease 
(CHD) events in Chinese men and women aged 35–
84, 2000–2029 from the CHD Policy Model-China. 
Rates are CHD events per 100,000 person-years. b. Pre-
dicted ten year rates of coronary heart disease (CHD) 
deaths in Chinese men and women aged 35–84, 2000–2029 
from the CHD Policy Model-China. Rates are deaths per 
100,000 person-years.
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overall aging, approximately 70% of older parents are
financially dependent on their children in China,[56] and
current population policies will lead to a diminishing
younger population able to support aging parents.[57] As
a result, the aged dependency ratio (persons >65 years
old/persons 15–64 years old) is expected to more than
double in China between 2000 and 2029,[1] while
increasing numbers of persons >65 years old will be living
with CHD and other chronic diseases. In terms of the bur-
den of CHD in working persons and the increasing
dependency ratio, our results replicate those of Leeder et
al.'s analysis of the macroeconomic impact of cardiovas-
cular disease in China in the years 2000, 2030, and
2040.[9]
Ongoing cohort studies in China have demonstrated
worsening trends in CHD risk factors, such as dyslipi-
demia, hypertension, obesity, and diabetes.
[26,46,53,55,58-61] Smoking prevalence in Chinese men
remains high at approximately 60%.[52] Although risk
factor levels may continue to increase in a rapidly devel-
oping and urbanizing China, we held risk factors at their
2000 levels for the present analysis. We therefore may
have underestimated the potential magnitude of the epi-
demic of CHD in China. On the other hand, if the decline
in CHD case-fatality rates observed in the Beijing Sino-
MONICA Study population from 1983–2004 is general-
izeable to all of China, this might lead to overestimation
of future CHD mortality, depending on the magnitude of
increase in CHD incidence and decline in CHD case-fatal-
ity rate. A future trend in declining CHD case-fatality was
not modeled in the primary analysis, but a sensitivity
analysis assuming the lower CHD case-fatality rates
observed recently in Beijing 1999–2004 predicted almost
four million fewer CHD deaths over 2000–2029, but a
12% increase in CHD prevalence. Declines in case-fatality
rates may continue due to increased uptake of CHD treat-
ments,[11,62] or to more widespread diagnosis of less
severe CHD cases. Recent declines in CHD case-fatality in
China suggest that the trend toward declining CHD mor-
tality and increased CHD prevalence documented in the
U.S.[16,63,64] and other developed nations in recent dec-
ades may eventually occur in China.
Our model's projections rely heavily on reliable CHD
mortality estimates for China, so we conducted sensitivity
analyses to demonstrate the variability in the model's pre-
dictions under different cause-specific mortality assump-
tions. Though estimated cumulative numbers of CHD
events and deaths increased substantially when we
defined more ill-defined cardiovascular coded deaths as
CHD or assumed the higher proportion of CHD deaths
reported by the Global Burden of Disease Study, the same
proportional increase in CHD outcomes over time per-
sisted under these alternate mortality assumptions. The
proportion of total deaths coded into ill-defined cardio-
vascular codes was less than 1% in the CHEFS, so misclas-
sification due to improper ICD coding of CHD deaths did
not likely bias our main simulation results. Our CHD
mortality estimate for Chinese adults aged 35–84 years in
2002 (486,00 deaths) was more than 20% lower than the
number reported by the Global Burden of Disease investi-
gators for the same year and age range (590,000).[36]
Overall mortality and population assumptions were the
same, therefore differences between the Global Burden
estimates and our main simulation results stem from their
assumed higher proportion of CHD deaths, particularly in
Chinese women. Official Chinese vital statistics are
incomplete,[65,66] particularly in rural areas.[66] Global
Table 6: Main simulation: predicted years of life lost (YLL), years 
of life lost due to disability (YLD), and disability-adjusted life 
years (DALYs) attributable to CHD in Chinese adults aged 35–84 
years, 2000, 2010, 2020, and 2030.
Year Disability-Adjusted Life Years*
2000 CHD deaths 457,000
Incident non-fatal MI 472,000
Incident angina 227,000
Incident heart failure 94,000
YLL 7,650,000
YLD 392,000
DALYs 8,042,000
DALYs per 1,000 persons 16.1
2010 CHD deaths 606,000
Incident non-fatal MI 618,000
Incident angina 325,000
Incident heart failure 124,000
YLL 10,196,000
YLD 534,000
DALY 10,730,000
DALYs per 1,000 persons 16.5
2020 CHD deaths 762,000
Incident non-fatal MI 789,000
Incident angina 366,000
Incident heart failure 158,000
YLL 12,639,000
YLD 603,000
DALY 13,242,000
DALYs per 1,000 persons 18.2
2030 CHD deaths 992,000
Incident non-fatal MI 1,015,000
Incident angina 437,000
Incident heart failure 203,000
YLL 15,649,000
YLD 706,000
DALY 16,356,000
DALYs per 1,000 persons 20.4
*DALY estimates reported in this table were not discounted and 
were not age weightedBMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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Burden of Disease cause of death estimates draw from the
Chinese Ministry of Health-Vital Registration System and
the Disease Surveillance Points system,[49] and the pro-
portion of deaths attributable to CHD among the elderly
differs by almost 3% between these two sources.[66] The
CHEFS serves as the main source for our CHD mortality
rate estimates. The CHEFS employed the same standard
two-tiered mortality assessment protocol nationwide, and
therefore may represent a more reliable source of age- and
sex-specific cause of death estimates. Proposed improve-
ments to death registration capacity, both globally[67]
and in China,[66] may minimize future uncertainty
regarding CHD mortality. Regarding our disability esti-
mates, because older age is the most potent risk factor for
CHD, our DALY estimates were dramatically lower when
age weights were applied, though the trend toward
increasing DALYs with time remained.
The main strength of the current analysis is that it mod-
eled CHD in the entire adult population of China, result-
ing in a detailed examination of the impact of the growing
and aging of the Chinese population on the future epi-
demic of CHD. However, our cardiovascular disease pre-
diction model for China has limitations. Stroke currently
is a far more common cause of death in China than is
CHD. It is a major limitation that the current version of
the CHD Policy Model-China includes the impact of
stroke as a component of non-CHD mortality but does
not specifically compute the annual or cumulative
number of strokes. CHD prediction in the Policy Model-
China relies heavily on a single Chinese cohort study.
However, the Cox model coefficients from the CMCS are
similar to those published from another Chinese
cohort.[46] The Policy Model-China risk function was cal-
ibrated using nationally-representative Chinese mortality
data, [8] and in this analysis, age- and sex-specific rates of
CHD, CHD deaths, and non-CHD deaths remained stable
over the 30 year simulation. Nonetheless, our model may
not be fully representative of China, which is a large,
multi-ethnic, and multi-cultural nation undergoing rapid
change. Although the BRIG study included CHD patients
from all over China in tertiary- and secondary-level hospi-
tals, patient or hospital selection bias may have resulted in
revascularization rates higher than those representative of
China as a whole. The Rose questionnaire has not been
validated as a tool for diagnosing angina in Chinese sub-
jects, but our prevalence estimates relied less on Rose
questionnaire-reported angina and more on incident
angina identified in clinical settings (presenting for medi-
cal attention and coded as ICD-9 413 in the CMCS
cohort). As a result, we may have excluded milder angina
and underestimated the burden of angina in Chinese
adults, especially in females.[68,69] Lastly, our estimates
of CHD incidence may be biased by the fact that estimates
of CHD events in the population diagnosed with CHD
were derived from hospital databases and clinical trials
describing North American populations and cohorts.
Conclusion
Our results demonstrate the joint effects of population
growth and aging on the CHD epidemic in China. The
patterns of CHD events, CHD deaths, and disability-
adjusted life years that we found suggest that while an
aging Chinese population will lead to steep increases in
the number of CHD events and deaths in persons  65
years old in the coming decades of this century, the pre-
dominant burden of CHD will continue to rest on the
working population <65 year old.
Abbreviations
CHD: coronary heart disease; DALY: disability-adjusted
life year; BMI: body mass index; LDL: low density lipopro-
tein cholesterol; HDL: high density lipoprotein choles-
terol; BP: blood pressure; WHO: World Health
Organization; MONICA: Monitoring Trends and Determi-
nants in Cardiovascular Disease project; CMCS: Chinese
Multi-provincial Cohort Study; InterASIA: International
Collaborative Study of Cardiovascular Disease in Asia
Study; CHEFS: China National Hypertension Survey Epi-
demiology Follow-up Study; BRIG: Bridging the Gap in
CHD secondary prevention study; PCI: percutaneous cor-
onary intervention; CABG: coronary artery bypass graft
surgery.
Competing interests
The authors declare that they have no competing interests.
Predicted annual disability-adjusted life years (DALY) due to  CHD by age <65 years or  65 years in Chinese adults 35–84  years old in 2000, 2010, 2020, and 2030, the CHD Policy  Model-China Figure 4
Predicted annual disability-adjusted life years 
(DALY) due to CHD by age <65 years or  65 years in 
Chinese adults 35–84 years old in 2000, 2010, 2020, 
and 2030, the CHD Policy Model-China.
0
2,000,000
4,000,000
6,000,000
8,000,000
10,000,000
12,000,000
14,000,000
16,000,000
18,000,000
2000 2010 2020 2030
D
i
s
a
b
i
l
i
t
y
-
A
d
j
u
s
t
e
d
 
L
i
f
e
 
Y
e
a
r
s
 
(
D
A
L
Y
s
)
DALYs age 65-84
DALYs age 35-64
29% 
28% 
 
30% 
33% 
71% 
72% 
 
70% 
67% BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
Page 11 of 14
(page number not for citation purposes)
Authors' contributions
AM conceived of the study, selected the computer model
inputs, adapted and calibrated the computer model, con-
ducted the analysis, and authored the first draft of the
manuscript. DZ participated in the study design, super-
vised data analyses and contributed editorially to the
manuscript, DG participated in the study design and con-
tributed editorially to the manuscript, PC participated in
the study design, consulted on the adaptation, calibration,
and analytic use of the computer model and contributed
editorially to the manuscript, C C-S conducted statistical
analyses, JC participated in the study design, conducted
statistical analyses and contributed editorially to the man-
uscript, JL contributed editorially to the manuscript, JH
participated in the study design, supervised data analyses,
and contributed editorially to the manuscript, LG assisted
with conception of the study, participated in model and
study design, and had final editorial approval for the fin-
ished manuscript.
Additional material
Additional file 1
Supplementary appendix. Additional materials describing the model 
assumptions and methods.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-8-394-S1.pdf]
Table 7: Sensitivity analyses
Decades Sensitivity Analysis Coronary Heart
Disease Events
Coronary Heart
Disease Deaths
Non-coronary Deaths
Incremental
difference
%Change Incremental
difference
%Change Incremental
difference
%Change
2000–2029 More liberal ICD definition
of CHD*
Total 9,973,000 20.8 3,561,000 17.4 -3,270,000 -1.2
Men 7,452,000 24.8 2,616,000 21.3 -2,605,000 -1.6
Women 2,521,000 14.1 945,000 11.5 -665,000 -0.6
2000–2029 Higher proportion of deaths
due to CHD, Global Burden
of Disease Study, 2002[36]
Total 10,788,000 22.5 4,732,000 23.1 -4,683,000 -1.7
Men 2,267,000 7.5 657,000 5.4 -723,000 -0.4
Women 8,521,000 47.5 4,074,000 49.6 -3,960,000 -3.4
2000–2029 Higher CHD case-fatality
rate†
Total -3,031,243 -6.3 4,709,000 23.0 -1,075,000 -0.4
Men -1,787,000 -5.9 2,978,000 24.2 -762,000 -0.5
Women -1,244,000 -6.9 1,730,000 21.1 -313,000 -0.3
2000–2029 Lower CHD case-fatality
rate‡
Total 324,000 1.5 -3,992,000 -19.5 814,000 <0.01
Men 447,000 0.7 -2,289,000 -18.7 515,000 <0.01
Women -123,000 -0.7 -1,704,000 -20.8 299,000 <0.01
Incremental differences in predicted CHD events and non-CHD deaths compared with the main simulation in Chinese adults 35–84 years old over 
the years 2000–2029, under alternate mortality assumptions
* CHD defined as myocardial infarction (ICD-9 410, 412 or ICD-10 I21, I22), angina and other CHD (ICD-9 411, 413 and 414, or IC-10 I20, I23–
I25), and a fixed proportion of "ill-defined" cardiovascular disease coded events and deaths.[33] (ICD-9 codes 427.1, 427.4, 427.5, 428, 429.0, 429.1, 
429.2, 429.9, 440.9 or ICD-10 I47.2, I49.0, I46, I50, I51.4, I51.5, I51.9, and I70.9). The liberal coding method used the same ICD codes described 
above, but assumed that a higher proportion of CHD deaths were mis-coded into the "ill-defined" cardiovascular codes, so more deaths assigned 
these ill-defined codes are counted as CHD deaths.[33]
†Higher case-fatality rates assumed for China in 2000 by the Global Burden of Disease Study – age trended, overall 62% for men and 72% for 
women.[34]
‡Lower case-fatality rates observed in the Sino-MONICA Beijing population over 1999–2004 averaged for age 25–74 years – age trended, overall 
40% for men and 49% for women (Personal communication, Dong Zhao, M.D., Ph.D., April, 2008)BMC Public Health 2008, 8:394 http://www.biomedcentral.com/1471-2458/8/394
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